Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    Oncology nurse education
    Clinical and Pharmaceutical Nurse Educators Collaborate to Bring Training to Nurses and Improve Patient Care
    January 13, 2023
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    Pancreatic cancer
    Oncology Nurse Uses Retirement to Help Patients and Healthcare Professionals Understand Pancreatic Cancer Biomarker Testing Results
    November 11, 2022
    The Life of Marie Curie and Her Contributions to Oncology
    Cancer treatments
    The Life of Marie Curie and Her Contributions to Oncology
    November 07, 2022
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    Patient safety
    Post-Flooding Natural Disaster Cancer Considerations and Patient Education Points
    September 28, 2022
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    Radiation therapy
    Can Patients Use Continuous Glucose Monitors During Radiation Therapy for Cancer?
    August 19, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Genetics & genomics

    Genetic Disorder Reference Sheet: BAP1
    Genetics & genomics

    Genetic Disorder Reference Sheet: BAP1

    Isolated in 1998 as a tumor suppressor gene, BAP1 pathogenic variants have been identified in at least 200 families. More cases will be found as germline pathogenic variant testing becomes more readily available and routinely offered to patients with cancer.

    January 17, 2023
    Build Your Confidence in Next-Generation Sequencing With Nursing Toolkits and Resources
    Genetics & genomics

    Build Your Confidence in Next-Generation Sequencing With Nursing Toolkits and Resources

    Essential biomarker testing technologies like next-generation sequencing are increasing our comprehension of cancer genetics and genomics. Biomarker testing results provide prognostic and predictive information about a tumor’s biology and growth to guide treatment decisions. Patients with cancer are turning to their oncology nurses to help them understand their complex test results and corresponding recommended treatment plans, yet many oncology nurses have minimal, if any, formal training in the area.

    December 29, 2022
    Genetic Disorder Reference Sheet: HOXB13
    Genetics & genomics

    Genetic Disorder Reference Sheet: HOXB13

    An altered HOXB13 gene may increase a patient’s risk for developing prostate cancer. The HOXB13 gene is expressed in the prostate beginning in early development and affects prostate cell proliferation and differentiation and androgen receptor regulation. When it acts as a tumor suppressor gene, HOXB13 codes for a protein that regulates cell division. However, altered copies of HOXB13 are inactivated, meaning that it does not function properly or does not produce the protein it codes for, resulting in uncontrolled cell division.

    November 30, 2022
    Genetic Counselors Help Patients and Oncology Nurses Predict Current and Future Cancer Diagnoses
    Genetics & genomics

    Genetic Counselors Help Patients and Oncology Nurses Predict Current and Future Cancer Diagnoses

    Many of our patients are individuals who haven’t developed cancer but might have a concerning family history of the disease. We rely on healthcare providers like oncology nurses to identify individuals with concerning cancer histories and refer them to genetic counselors for a complete risk assessment, including genetic testing when appropriate, to determine their risk and recommend proactive measures to reduce it.

    November 01, 2022
    Understand Genomic Variants to Confidently Educate Your Patients
    Genetics & genomics

    Understand Genomic Variants to Confidently Educate Your Patients

    Nurses’ consistent and correct use of genomics terminology is critical to reduce confusion and provide safe genomics care to patients and their families, especially when explaining the meaning of genomic tests or findings.

    October 13, 2022
    Oncology Nurses’ Role in Translating Biomarker Testing Results
    Genetics & genomics

    Oncology Nurses’ Role in Translating Biomarker Testing Results

    As oncology biomarker testing becomes a routine part of clinical practice, so does first-line use of their associated targeted therapies such as monoclonal antibodies, checkpoint inhibitors, and tyrosine kinase inhibitors.

    September 15, 2022
    Dietary-Produced Ketone May Halt Colon Cancer
    Cancer research

    Dietary-Produced Ketone May Halt Colon Cancer

    A compound the body produces when fasting or following a ketogenic diet may slow or stop the growth of colorectal cancer (CRC) cells, according to study results published in Nature.

    August 24, 2022
    Genetic Disorder Reference Sheet:  Multiple Endocrine Neoplasia Type 2
    Genetics & genomics

    Genetic Disorder Reference Sheet: Multiple Endocrine Neoplasia Type 2

    Multiple endocrine neoplasia type 2 is an autosomal dominant disease that occurs because of germline pathogenic variants in the rearranged during transfection (RET) proto-oncogene. The RET gene was isolated in 1993 and pathogenic variants affect 1–10 per 100,000 people. Approximately 50% of cases are de novo.

    August 04, 2022
    Genetic Disorder Reference Sheet: Multiple Endocrine Neoplasia Type 1
    Genetics & genomics

    Genetic Disorder Reference Sheet: Multiple Endocrine Neoplasia Type 1

    Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant genetic disease affecting about 1 in 30,000 people. Pathogenic variants in the MEN1 gene are associated with benign and malignant tumors in the parathyroid glands, pituitary gland, pancreas, duodenum, and stomach.

    July 07, 2022
    Genomics’ Red Flag Rule  of Too and Two
    Genetics & genomics

    Genomics’ Red Flag Rule of Too and Two

    I often use mnemonics, a memory tool, to simplify learning. Mnemonics can be any pattern of letters, numbers, words, images, or other relatable associations that help you remember.

    June 27, 2022
    Minority Populations Represent Nearly Half of 100,000 Whole Genome Sequences for Researchers Through All of Us
    Genetics & genomics

    Minority Populations Represent Nearly Half of 100,000 Whole Genome Sequences for Researchers Through All of Us

    Among the first set of nearly 100,000 whole genome sequences from participant partners in the National Institutes of Health’s (NIH) All of Us Research Program, “about half come from people who self-identify with a racial or ethnic minority group,” Joshua Denny, MD, MS, All of Us chief executive officer, and Lawrence Tabak, DDS, PhD, NIH acting director, said. “That’s extremely important because, until now, over 90% of participants in large genomic studies were of European descent. This lack of diversity has had huge impacts—deepening health disparities and hindering scientific discovery from fully benefiting everyone.”

    May 16, 2022
    Genetic Disorder Reference Sheet: Von Hippel-Lindau Syndrome
    Genetics & genomics

    Genetic Disorder Reference Sheet: Von Hippel-Lindau Syndrome

    An inherited disorder characterized by the formation of benign and malignant tumors and cysts throughout the body, Von Hippel-Lindau syndrome (VHL) occurs with an altered VHL tumor suppressor gene with autosomal dominant transmission. Estimated incidence is 1 in 36,000 people, both males and females equally, and the mean age of onset is 26 years. About 20% of patients with VHL are the first person in their family to have the pathogenic variant (i.e., de novo). The diagnosis is made with germ­line biomarker testing.

    April 11, 2022
    FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum
    U.S. Food and Drug Administration (FDA)

    FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum

    On April 5, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to alpelisib (Vijoice®) for adult and pediatric patients aged two and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy.

    April 07, 2022
    The Oncology Nurse’s Role in Identifying Patients for Cancer Genetics Counseling
    Genetics & genomics

    The Oncology Nurse’s Role in Identifying Patients for Cancer Genetics Counseling

    During personal and family medical history assessments, many patients report multiple cancer diagnoses in their family or concerns that other family members might be at increased risk for developing cancer. Patients and families might also ask their nurse about risk or parameters for genetic testing. Timely and appropriate referral to genetics professionals for counseling and possible testing for germline risk of malignancy enables individuals at increased risk to follow recommended surveillance and consider surgery and other preventive strategies, ultimately decreasing their risk of cancer-related morbidity and mortality.

    March 31, 2022
    Advocate for Equal Access for Next Generation Sequencing and Clinical Trials
    Ethics in nursing

    Advocate for Equal Access for Next Generation Sequencing and Clinical Trials

    Janice is an oncology nurse in a rural community cancer center. Only one of the three oncologists in the practice discusses clinical trials with their patients and typically not until after patients complete two to three lines of therapy. Also, the practice does not have a process for when to order next generation sequencing (NGS). Janice feels it is not ethical that the patients coming to the clinic do not have equal access to those important services.

    March 21, 2022
    Genetic Disorder Reference Sheet: PALB2
    Genetics & genomics

    Genetic Disorder Reference Sheet: PALB2

    PALB2 refers to partner and localizer of BRCA2. The gene was isolated in 2007 and is the third most common gene associated with breast cancer risk. Both men and women are at increased risk for developing multiple cancers if they have a pathogenic PALB2 variant (see sidebar).

    March 15, 2022
    Mama at the Bar: Using Analogies to Understand Targeted Therapies
    Nursing education

    Mama at the Bar: Using Analogies to Understand Targeted Therapies

    Analogies and visuals are powerful learning tools. If you’re one of the many nurses whose eyes glaze over when approaching genomics, consider connecting the “omics” concepts to interpretative visuals, clinical practice, and everyday life examples to enhance your learning and make the concepts more relevant to you. Here’s an example of how it can be done.

    March 10, 2022
    Never Smokers With Lung Cancer May Have One of Three Molecular Subtypes
    Lung Cancer

    Never Smokers With Lung Cancer May Have One of Three Molecular Subtypes

    Most lung cancers in patients who have no smoking history are the result of natural genetic variants in the body that can be classified into one of three molecular subtypes, researchers reported in study finding published in Nature Genetics.

    January 26, 2022
    Genetic Disorder Reference Sheet: CDH1 and Hereditary Diffuse Gastric Cancer
    Genetics & genomics

    Genetic Disorder Reference Sheet: CDH1 and Hereditary Diffuse Gastric Cancer

    Pathogenic variants in the CDH1 gene are associated with hereditary diffuse gastric cancer (HDGC), a poorly differentiated adenocarcinoma that infiltrates into the stomach wall. It causes the stomach wall to thicken without forming a distinct mass, which limits effective screening strategies.

    January 18, 2022
    Help Patients Understand Biomarker Test Results and Clinical Trials Options
    Genetics & genomics

    Help Patients Understand Biomarker Test Results and Clinical Trials Options

    Many of today’s new drug approvals and standard-of-care treatments have a companion diagnostic test that identifies biomarkers in a patient’s tumor tissue or blood to determine whether they are an appropriate candidate for the therapy. When those results show that they’re not a good match for the U.S. Food and Drug Administration (FDA)-approved treatment, the findings may identify a biomarker-directed clinical trial as an alternative option. Here’s how oncology nurses can help patients understand which clinical trials listed on their test results might be an option for them.

    December 16, 2021
    Oncology Nursing Society Issues a Call to Action for Using Appropriate Genomics Terminology for Safety and Quality
    Press Releases

    Oncology Nursing Society Issues a Call to Action for Using Appropriate Genomics Terminology for Safety and Quality

    The Oncology Nursing Society (ONS) is calling all oncology nurses to become fluent in the ONS Genomics Taxonomy terms and to use them in their practice. Using consistent and correct genomics terminology minimizes confusion and misconceptions and contributes to the high quality and safe delivery of cancer care.

    December 09, 2021
    New NIH Program Aims to Increase Gene Therapies for Rare Diseases
    Cancer research

    New NIH Program Aims to Increase Gene Therapies for Rare Diseases

    To accelerate the development of gene therapies for the 30 million Americans who have been diagnosed with a rare disease, in October 2021 the National Institutes of Health (NIH), U.S. Food and Drug Administration (FDA), 10 pharmaceutical companies, and five nonprofit organizations announced the creation of the Bespoke Gene Therapy Consortium (BGTC). The consortium is optimizing and streamlining the gene therapy development process to help fill the unmet medical needs of people with rare diseases.

    November 18, 2021
    Genetic Disorder Reference Sheet: Familial Adenomatous Polyposis
    Genetics & genomics

    Genetic Disorder Reference Sheet: Familial Adenomatous Polyposis

    Individuals with 10–100+ polyps may have a germline pathogenic variant in the APC gene, placing them at higher risk for developing colorectal, gastrointestinal, and other cancers. The condition is known as familial adenosis polyposis (FAP), and loss of function in the APC gene is the first step in the adenoma-to-carcinoma sequence. Some people have an attenuated form (aFAP), with delayed polyp growth and fewer polyps (see sidebar). As many as 20% are de novo, meaning that they are the first in their family to have an identified pathogenic variant.

    November 04, 2021
    Genetic Counselors Help Patients and Providers Understand Biomarker Testing Goals and Results
    Targeted therapy

    Genetic Counselors Help Patients and Providers Understand Biomarker Testing Goals and Results

    Genetic counselors have a unique ability to explain complex genetic information to patients, providers, and our healthcare colleagues and to empower patients to take an active role in their healthcare decisions. We review biosignature data points and help explain the difference between variants that were acquired (somatic) versus those that may have a germline component, or possibly inherited from a parent. By working with oncology teams, genetic counselors provide guidance on potential next steps to evaluate variation occurrences and how providers, patients, and their families can use the information to guide their care.

    November 02, 2021
    Genetic Disorder Reference Sheet: ATM Pathogenic Variants
    Genetics & genomics

    Genetic Disorder Reference Sheet: ATM Pathogenic Variants

    An estimated 1%–2% of adults have one pathogenic ataxia telangiectasia mutated (ATM) gene variant (heterozygous) and are considered carriers. People who are homozygous (two altered copies) have ataxia-telangiectasia (A-T), a hereditary condition that often appears in childhood and is characterized by progressive neurologic problems that lead to difficulty walking and an increased risk for developing various malignancies. Children with A-T may begin staggering and appear unsteady (ataxia) shortly after learning to walk.

    October 18, 2021
    NIH Provides $185 Million to Advance Understanding of Human Genome Functions
    Cancer research

    NIH Provides $185 Million to Advance Understanding of Human Genome Functions

    To drive the advancement of our understanding of the human genome, the National Institute of Health (NIH) is providing $185 million in funding over the next five years, the agency announced in September 2021.

    October 15, 2021
    Proton Pump Inhibitors May Boost Radiation’s Effects
    Radiation therapy

    Proton Pump Inhibitors May Boost Radiation’s Effects

    September 29, 2021
    This Is Why Red Meat Increases Colorectal Cancer Risk
    Cancer research

    This Is Why Red Meat Increases Colorectal Cancer Risk

    Frequent red and processed meat consumption leaves a specific pattern of DNA damage in colorectal cells that contributes to the formation of tumors, researchers reported in study findings published in Cancer Discovery.

    September 15, 2021
    A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities
    Cancer research

    A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities

    When chimeric antigen receptor (CAR) T-cell therapies were first approved for cancer in 2017, nurses didn’t have years of clinical practice experience with the treatment to understand its full scope of nursing implications yet. Now that nearly five years have passed—and new CAR T-cell therapies have been approved, bringing the total number of treatments to five as well—oncology nurses and nurse scientists have built a robust knowledge base.

    September 14, 2021
    Prognostic Biomarkers May Help Predict Rhabdomyosarcoma Outcomes
    Research

    Prognostic Biomarkers May Help Predict Rhabdomyosarcoma Outcomes

    TP53 and MYOD1 variants are associated with more aggressive forms of rhabdomyosarcoma, a rare childhood cancer, and poorer outcomes, according to the results of the largest international genomic profiling study of the disease. The findings, which were published in the Journal of Clinical Oncology, have implications for somatic biomarker testing to guide tailored treatment approaches.

    September 09, 2021
    Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS
    Genetics & genomics

    Whole-Genome Sequencing May Guide Treatment Choices for AML and MDS

    When compared to conventional testing on the same samples from patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), whole-genome sequencing–based testing detected the same abnormalities—and new genetic information in about a quarter of patients, potentially changing treatment selection for more than half of those patients, researchers said in the New England Journal of Medicine.

    August 18, 2021
    New Form of CAR T Cells May Target Genetic Alteration Common to All Cancers
    Immunotherapy

    New Form of CAR T Cells May Target Genetic Alteration Common to All Cancers

    Scientists created a new cancer immunotherapy approach that uses a new type of CAR T cells to stimulate an immune response against cells that are missing one gene copy. They reported their findings in Proceedings of the National Academy of Sciences.

    July 28, 2021
    What Is CRISPR?
    Research

    What Is CRISPR?

    Clustered regularly interspaced short palindromic repeats (CRISPR) is a commonly seen term for readers of science news and literature across a variety of industries. But reading the word often doesn’t automatically translate to understanding it and its implications. Here’s what oncology nurses need to know about CRISPR.

    July 26, 2021
    Genetic Disorder Reference Sheet: MUTYH-Associated Polyposis
    Genetics & genomics

    Genetic Disorder Reference Sheet: MUTYH-Associated Polyposis

    MUTYH-associated polyposis (MAP) is an autosomal recessive hereditary cancer syndrome. It’s most commonly seen in people of northern European ancestry, where an estimated 1 in 20,000–40,000 have MAP (two pathogenic variants on opposite chromosomes) and 1%–2% have one MUTYH pathogenic variant.

    July 08, 2021
    Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Cancers
    Clinical practice

    Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Cancers

    BRCA1- or BRCA2-associated hereditary breast and ovarian cancer is the most common form of hereditary breast and ovarian cancer. The prevalence of BRCA1 and BRCA2 pathogenic variants in the general population is estimated at 1 in 400–500 people, although it increases to 1 in 40 for those of Ashkenazi Jewish ancestry, which is linked to three founder pathogenic variants (BRCA1 c.68_69delAG, BRCA1c.5266dupC, and BRCA2 c.5946delT). 

    May 06, 2021
    Genomics Test Guides Treatment Decisions for Prostate Cancer
    Genetics & genomics

    Genomics Test Guides Treatment Decisions for Prostate Cancer

    The Decipher genomics test, which measures activity of 22 genes among seven known cancer pathways, independently estimates patients’ risk of prostate cancer metastasis, death, and overall survival and helps identify patients most likely to benefit from hormone therapy, researchers reported in study findings published in JAMA Oncology.

    May 05, 2021
    NHGRI Proposes Action Agenda for Building Diverse Genomics Workforce
    Genetics & genomics

    NHGRI Proposes Action Agenda for Building Diverse Genomics Workforce

    Thanks to the National Institutes of Health’s National Human Genome Research Institute (NHGRI), cancer treatments and cures once out of reach are now closer than ever. So is our understanding about the human condition. As part of its latest strategic vision for the future of human genomics, NHGRI announced an action agenda to substantially enhance the industry’s workforce diversity by 2030. 

    April 22, 2021
    The Case of the Targeted Therapy Toxicity
    Genetics & genomics

    The Case of the Targeted Therapy Toxicity

    Tyrone is a 74-year-old man with a history of acute myeloid leukemia (AML), type 2 diabetes, and hypertension who was admitted to the hospital after lab results revealed 40% circulating blasts in his peripheral blood that was concerning for relapsed disease. He was diagnosed with AML three years ago and achieved remission after treatment with a hypomethylating agent. 

    April 09, 2021
    Genetic Disorder Reference Sheet: CHEK2 Gene Pathogenic Variants
    Genetics & genomics

    Genetic Disorder Reference Sheet: CHEK2 Gene Pathogenic Variants

    The CHEK2 (checkpoint kinase 2) tumor suppressor gene provides cells with instructions for making a protein known as CHK2, which becomes active when the cell’s DNA is damaged or strands of it break. CHEK2 halts cell division and enables either cell repair or destruction. Without a properly functioning CHEK2 gene, cells lose a key restraint on their growth which may lead to uncontrolled cells and possibly malignancy. CHEK2*1100delC is the most common pathogenic variant and most prevalent in European populations.

    March 23, 2021
    Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)
    Genetics & genomics

    Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)

    Lynch syndrome, now referred to as hereditary nonpolyposis colorectal cancer (HNPCC), was first identified in a family in 1895. In 1966, Henry Lynch reported a series of families with colon and other cancers in the Nebraska area. Today, the evidence shows that HNPCC is associated with germline pathogenic variants in the MLH1, MSH2, MSH6, PMS2, and EPCAM genes.

    January 25, 2021
    Genomics Provides Insight on Exceptionally Responding Patients
    Genetics & genomics

    Genomics Provides Insight on Exceptionally Responding Patients

    Patients with cancer who experience unexpected and long-lasting treatment outcomes are considered exceptional responders, but researchers and clinicians had no insight as to why the patients did so well with treatment. Results of a new study now show that genomic characterizations of cancer can uncover genetic alterations that may contribute to the phenomenon, researchers reported in Cancer Cell.

    January 13, 2021
    Genomics May Trick PARP Inhibitors to Treat More Cancers
    Research

    Genomics May Trick PARP Inhibitors to Treat More Cancers

    Turning on the body’s inflammasome with epigenetic therapy may improve the efficacy of PARP inhibitors across multiple tumor types, possibly expanding the therapy’s application to new cancers, researchers reported in Proceedings of the National Academy of Sciences.

    December 23, 2020
    What Is the Role of Genetic Counselors in Cancer Care?
    Genetics & genomics

    What Is the Role of Genetic Counselors in Cancer Care?

    Our understanding of cancer’s genetic components is constantly growing, with new cancer susceptibility genes discovered every year that change how we screen for and treat cancer. Genetics specialists keep up with the latest information and implications of genetic results is and can be a great addition to comprehensive oncology teams.

    December 15, 2020
    Harnessing the Power of Genes
    Genetics & genomics

    Harnessing the Power of Genes

    Since the mapping of the human genome in 2003, genetic testing has rapidly evolved from single-gene tests to more complex profiles that measure multiple genes; it’s now part of standard care for many cancer types. Precision oncology allows clinicians to take patient-specific genomic factors into consideration when making treatment decisions, which can lead to improved outcomes, lower overall cost, and fewer side effects.

    December 01, 2020
    Oncology Nurses Have a Role in Genomics Throughout the Cancer Care Continuum
    Genetics & genomics

    Oncology Nurses Have a Role in Genomics Throughout the Cancer Care Continuum

    Cancer genomics influences all oncology nursing roles. Walking through the cancer care continuum shows how genomics—and oncology nursing—are involved at every level.

    November 26, 2020
    Winning Team Reduces Disparities to Biomarker Testing in First-Ever ONS Hackathon
    Press Releases

    Winning Team Reduces Disparities to Biomarker Testing in First-Ever ONS Hackathon

    The Oncology Nursing Society (ONS) launched its inaugural ONS Hackathon™ on November 9, 2020, a competition designed to identify innovative ways to address challenging issues in the delivery of quality cancer care. Meghan O. Coleman, DNP, CRNP, and Alison McDaniel, BSN, RN, OCN®’s winning project, Evidence-Based Quality Understanding in Pathology, provided ways to solve the problem of unequal access to biomarker and other genetic and genomic testing.

    November 23, 2020
    Get Answers to Your Most Frequently Asked Genomics and Cancer Questions
    Genetics & genomics

    Get Answers to Your Most Frequently Asked Genomics and Cancer Questions

    Approximately 700 members responded to ONS’s 2020 genomics survey, which gauged oncology nurses’ current genomic knowledge, applications in practice, and the specific questions they have about genetics and genomics. Here are the answers to the most frequently asked questions based on the survey responses.

    October 27, 2020
    Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations
    Breast cancer

    Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations

    In the United States, breast cancer is the most commonly diagnosed cancer in women. One in eight women will develop invasive disease in their lifetime with approximately 270,00 new cases diagnosed in the United States in 2019. Caucasian women have the highest incidence rate, whereas African American women are most likely to die from the disease. The five-year survival rate is 91%, with an estimated 3.8 million breast cancer survivors living in the United States.

    October 15, 2020
    What Is a Genomic Variant?
    Genetics & genomics

    What Is a Genomic Variant?

    The Human Genome Project determined the DNA sequence (order of base pairs) of the entire human genome. Humans are 99.9% identical at the level of base pair ordering, but the 0.1% difference contributes to disease risk. Upon completion of the human genetic blueprint, research turned to identifying and cataloguing genomic variation as well as determining the clinical relevance of variants.

    September 17, 2020
    FDA Approves Pralsetinib for Lung Cancer With RET Gene Fusions
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pralsetinib for Lung Cancer With RET Gene Fusions

    On September 4, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pralsetinib (Gavreto™) for adult patients with metastatic, RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

    September 10, 2020
    • Current page 1
    • Page 2
    • Page 3
    • Next page
    • Last page Last »
    Trending Topics
    • Research
    • Treatments
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Special Populations
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2023 Oncology Nursing Society
     
    Back to Top ▲